American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 362-365 , March 2008

Phosphate Binder Choice in Dialysis Patients: A Call for Evidence-Based Rather Than Marketing-Based Clinical Practice

  • Wolfgang C. Winkelmayer, MD, ScD

      Affiliations

    • Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationAddress correspondence to Wolfgang C. Winkelmayer, MD, ScD, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA 02120.
    • ,
  • Marcello Tonelli, MD

      Affiliations

    • University of Alberta, Edmonton, Canada

References 

  1. Rumberger JA, Brundage BH, Rader DJ, et al. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74:243–252
  2. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004;8:54–58
  3. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441
  4. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  5. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  6. Manns B, Stevens L, Miskulin D, et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004;66:1239–1247
  7. St. Peter WL, Liu J, Weinhandl E, et al. Comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) Randomized Trial Using Claims Data. Am J Kidney Dis. 2008;51:445–454
  8. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137
  9. Mitka M. Study probes best choice of drug to reduce phosphate in patients on dialysis. JAMA. 2007;298:1995–1996
  10. Lagakos SW. The challenge of subgroup analyses—reporting without distorting. N Engl J Med. 2006;354:1667–1669
  11. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46
  12. Manns B, Owen WF, Winkelmayer WC, et al. Surrogate markers in clinical studies: problems solved or created?. Am J Kidney Dis. 2006;48:159–166

PII: S0272-6386(08)00038-3

doi: 10.1053/j.ajkd.2008.01.004

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 362-365 , March 2008

Article Tools